Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Pieter SonneveldMeletios A DimopoulosMario BoccadoroHang QuachP Joy HoMeral BeksacCyrille HulinElisabetta AntonioliXavier LeleuSilvia MangiacavalliAurore PerrotMichele CavoAngelo BelottiAnnemiek BroijlFrancesca GayRoberto MinaInger S NijhofNiels W C J van de DonkEirini KatodritouFredrik SchjesvoldAnna Sureda BalariLaura RosiñolMichel DelforgeWilfried RoeloffzenTobias SilzleAnnette VangstedHermann EinseleAndrew SpencerRoman HajekArtur JurczyszynSarah LonerganTahamtan AhmadiYanfang LiuJianping WangDiego VieyraEmilie M J van BrummelenVeronique VanquickelbergheAnna Sitthi-AmornCarla J de BoerRobin CarsonPaula Rodriguez-OteroJoan BladéPhilippe Moreaunull nullPublished in: The New England journal of medicine (2023)
The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with respect to progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma. (Funded by the European Myeloma Network in collaboration with Janssen Research and Development; PERSEUS ClinicalTrials.gov number, NCT03710603; EudraCT number, 2018-002992-16.).